Detect-ION Launches End-to-End Volatilomics Services, Opening Its Laboratory to Research and Industry Partners

Single service agreement covers sample collection, point-of-care and lab-grade analysis, and
multivariate data analytics

TAMPA, Fla., Oct. 6, 2026 /PRNewswire/ -- Detect-ION, developer of next-generation mass spectrometry-based sensors and diagnostic platforms, today announced the launch of Detect-ION Analytical Services, making the volatilomics capabilities behind its clinical diagnostics and chemical sensors available to external collaborators for the first time.

For years, Detect-ION's in-house volatilomics laboratory, anchored by high-resolution mass spectrometry (HRMS), has served as the reference foundation for the company's own diagnostics and detection technologies. The new service offering extends that same infrastructure, and the team's experience using it, to academic, clinical, government and industry partners, building on lessons from successful clinical research pilots spanning lung cancer, malaria and several respiratory infections including tuberculosis. The company's work has been funded by the Intelligence Advanced Research Projects Activity (IARPA), the Defense Advanced Research Projects Agency (DARPA), the Defense Threat Reduction Agency (DTRA), the Defense Innovation Unit (DIU) and the Gates Foundation.

Services are delivered across three complementary tiers, allowing partners to match analytical power to the needs of each project:

• CLARION for in situ, point-of-care analysis wherever samples are generated
• Shimadzu TD-GC-MS for routine and targeted laboratory analysis
• Agilent TD-GC-HRMS (>25,000 FWHM resolution, <2 ppm mass accuracy) for untargeted discovery and reference-grade confirmation

Offerings include untargeted volatilomics discovery, targeted volatile and semi-volatile organic compound (VOC and SVOC) identification, method development and validation, confirmatory analysis, custom spectral library building, feasibility studies for new sample matrices, and multivariate data analytics. Supported sample types include breath, aerosols, urine headspace, environmental air, water, food and beverage, agricultural volatiles and chemical threat signatures. Services are provided for research and development purposes and are not intended for diagnosing or treating disease.

Unlike conventional contract laboratories, Detect-ION combines sample collection, analysis and data analytics under a single, customizable service agreement, sparing partners the cost and complexity of coordinating separate vendors. Standardized sample collection and analysis protocols keep results comparable across studies, sites and instruments. For projects with the right research fit, Detect-ION also offers clinical study development through its Breath Research Laboratory, including protocol design, IRB submission and support via its established relationship with WCG IRB, and participant enrollment.

Partners engaging with Detect-ION Analytical Services today will also be positioned to benefit from the company's upcoming product lines, which are designed to democratize volatilomics by making reference-grade volatile analysis accessible, affordable and deployable well beyond the traditional laboratory.

"We built this capability to answer our own hardest questions, in clinical breath diagnostics and in chemical threat detection, and we learned that generating the data is only half the job," said Ashish Chaudhary, Ph.D., founder, CEO and CTO of Detect-ION. "Our partners get the whole pipeline: collection, reference-grade chemistry and the analytics to turn thousands of features into answers they can publish and defend. Standardization has been a focus for us from day one, because volatilomics only earns its place in the clinic when results hold up from one study, one site and one instrument to the next. And as our CLARION and SPECTRAL product lines come to market, our service partners will be first in line to put them to work. Their questions; our collection, analysis and analytics; one contract."

To learn more or discuss a project, visit https://detect-ion.com/services/. Details on clinical study support are available at https://detect-ion.com/capabilities/.

About Detect-ION

Detect-ION is a deep-tech startup founded in 2021 and headquartered in a 4,000-square-foot laboratory in Tampa, Florida. The company solves complex, high-value detection problems that demand a multidisciplinary approach, drawing on organic chemistry, biochemistry, gas chromatography, mass spectrometry, vacuum technology, data analytics, systems engineering, artificial intelligence and machine learning to develop next-generation diagnostics and detection platforms. The company's diagnostics arm advances breath- and urine-based testing with leading clinical research institutions, including Mayo Clinic, the University of South Florida, Moffitt Cancer Center and Tampa General Hospital, and runs an on-site Breath Research Laboratory that accelerates clinical enrollment when needed. Detect-ION's mission is to democratize mass spectrometry through innovative solutions with wide-ranging applications in national security, public health, environmental monitoring and life sciences. Learn more at https://detect-ion.com.

SOURCE Detect-ION